Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
NCT05677100 ·
Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome
RecruitingAortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.
PhaseNA
TypeInterventional
Age21 Years
WherePhoenix, Arizona, United States + 47 more
SponsorProcyrion
▾Tap for detailsClick for full details — eligibility, all locations, contacts ELEVATE-HFpEF Clinical Study
RecruitingELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).
PhaseNA
TypeInterventional
Age40 Years
WherePhoenix, Arizona, United States + 43 more
SponsorMedtronic Cardiac Rhythm and Heart Failure
▾Tap for detailsClick for full details — eligibility, all locations, contacts PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
RecruitingThis is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm (Group 3) NYHA III Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class III HF patients, where patients have daily access to PAP data, including a randomized sub-study to evaluate a clinician-directed patient self-management strategy.
PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 49 more
SponsorEndotronix, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811 · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
RecruitingThis study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.
PhasePhase 3
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 289 more
SponsorNovo Nordisk A/S
▾Tap for detailsClick for full details — eligibility, all locations, contacts Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404 · Coronavirus Infection (COVID-19),
Pulmonary Arterial Hypertension, Urinary Tract Infections in Children
RecruitingThe study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Phase—
TypeObservational
Age0 Years – 20 Years
WherePhoenix, Arizona, United States + 50 more
SponsorDuke University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961 · Atherosclerotic Cardiovascular Disease in Patients With ESKD
RecruitingThis is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
PhasePhase 2 / Phase 3
TypeInterventional
Age18 Years
WhereDecatur, Alabama, United States + 541 more
SponsorCSL Behring
▾Tap for detailsClick for full details — eligibility, all locations, contacts Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
RecruitingThis trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
PhasePhase 3
TypeInterventional
Age18 Years – 99 Years
WhereBirmingham, Alabama, United States + 604 more
SponsorAmgen
▾Tap for detailsClick for full details — eligibility, all locations, contacts Assessment of CCM in HF With Higher Ejection Fraction
RecruitingThe AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
PhaseNA
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 104 more
SponsorImpulse Dynamics
▾Tap for detailsClick for full details — eligibility, all locations, contacts Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
RecruitingThis is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
PhasePhase 3
TypeInterventional
Age18 Years – 130 Years
WhereAlexander City, Alabama, United States + 844 more
SponsorAstraZeneca
▾Tap for detailsClick for full details — eligibility, all locations, contacts The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.
Phase—
TypeObservational
Age18 Years
WhereMesa, Arizona, United States + 27 more
SponsorImpulse Dynamics
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
NCT05636176 ·
Heart Failure RecruitingThis study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.
PhasePhase 3
TypeInterventional
Age18 Years
WhereAlexander City, Alabama, United States + 1116 more
SponsorNovo Nordisk A/S
▾Tap for detailsClick for full details — eligibility, all locations, contacts Left vs Left Randomized Clinical Trial
RecruitingThe investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with either a wide QRS (≥130 ms) or with/anticipated \>40% pacing who are already receiving current standard heart failure pharmacological therapy.
PhaseNA
TypeInterventional
Age18 Years
WhereGilbert, Arizona, United States + 70 more
SponsorBaylor College of Medicine
▾Tap for detailsClick for full details — eligibility, all locations, contacts Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
RecruitingThe purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.
PhaseNA
TypeInterventional
Age40 Years
WhereBirmingham, Alabama, United States + 19 more
SponsorAxon Therapies, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195 ·
Heart Failure, Heart Diseases, Cardiovascular Diseases
RecruitingThe purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 62 more
SponsorAbbott Medical Devices
▾Tap for detailsClick for full details — eligibility, all locations, contacts The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
NCT03142152 · Functional Mitral Regurgitation,
Heart Failure, Mitral Valve Insufficiency
RecruitingThe objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).
PhaseNA
TypeInterventional
Age18 Years
WhereGilbert, Arizona, United States + 91 more
SponsorCardiac Dimensions, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
RecruitingResearchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH that is caused by heart failure with preserved ejection fraction (HFpEF). Researchers want to know if the study treatment, sotatercept, can treat people with Cpc-PH caused by HFpEF. This is an extension study, which means people who took part in a certain study on sotatercept for Cpc-PH (called a parent study) may be able to join this study. In this extension study, people will take sotatercept and researchers will follow their health for a longer time. The main goal of this extension study is to learn about the long-term safety of sotatercept and if people tolerate it over a longer period of time.
PhasePhase 2
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 56 more
SponsorMerck Sharp & Dohme LLC
▾Tap for detailsClick for full details — eligibility, all locations, contacts His-Bundle Corrective Pacing in Heart Failure
NCT05265520 · Right Bundle-Branch Block,
Heart Failure, His-bundle Pacing
RecruitingThe investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).
PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 13 more
SponsorUniversity of Rochester
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297 · Neutropenia
RecruitingThe purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.
PhasePhase 3
TypeInterventional
Age12 Years
WherePhoenix, Arizona, United States + 113 more
SponsorX4 Pharmaceuticals
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RecruitingTX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
PhasePhase 2
TypeInterventional
Age18 Years – 83 Years
WherePhoenix, Arizona, United States + 85 more
SponsorTectonic Therapeutic
▾Tap for detailsClick for full details — eligibility, all locations, contacts REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368 · Aortic Stenosis
RecruitingThe purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
Phase—
TypeObservational
Age18 Years – 105 Years
WhereBirmingham, Alabama, United States + 70 more
SponsorMedtronic Cardiovascular
▾Tap for detailsClick for full details — eligibility, all locations, contacts